Evidence map›Paper›PMID 39201655›Full record

ArticleInternational journal of molecular sciences2024

Combination of Blood Adiponectin and Leptin Levels Is a Predictor of Biochemical Recurrence in Prostate Cancer Invading the Surrounding Adipose Tissue.

Atsuto Suzuki, Shinya Sato, Noboru Nakaigawa, Takeshi Kishida, Yohei Miyagi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Atsuto SuzukiMorphological Analysis Laboratory, Kanagawa Cancer Center Research Institute, Yokohama 241-8515, Kanagawa, Japan.ORCID 0000-0002-4072-9547
Shinya SatoMorphological Analysis Laboratory, Kanagawa Cancer Center Research Institute, Yokohama 241-8515, Kanagawa, Japan.
Noboru NakaigawaDepartment of Urology, Kanagawa Cancer Center, Yokohama 241-8515, Kanagawa, Japan.
Takeshi KishidaDepartment of Urology, Kanagawa Cancer Center, Yokohama 241-8515, Kanagawa, Japan.
Yohei MiyagiDepartment of Pathology, Kanagawa Cancer Center, Yokohama 241-8515, Kanagawa, Japan.

Funding

Japan Society for the Promotion of Science 23K08708Japan Society for the Promotion of Science JP20K09422
6 · The paper itself

Abstract

Biochemical recurrence is a process that progresses to castration-resistant prostate cancer (CRPC) and prediction of biochemical recurrence is useful in determining early therapeutic intervention and disease treatment. Prostate cancer is surrounded by adipose tissue, which secretes adipokines, affecting cancer progression. This study aimed to investigate the correlation between blood adipokines and CRPC biochemical recurrence. We retrospectively analyzed the clinical data, including preoperative serum adipokine levels, of 99 patients with pT3a pN0 prostate cancer who underwent proctectomy between 2011 and 2019. The primary outcome was biochemical recurrence (prostate-specific antigen: PSA > 0.2). We identified 65 non-recurrences and 34 biochemical recurrences (one progressed to CRPC). The initial PSA level was significantly higher (

Indexed as

AdiponectinAdipose TissueLeptinNeoplasm Recurrence, LocalProstate-Specific AntigenProstatic NeoplasmsAgedBiomarkers, TumorHumansMaleMiddle AgedPrognosisProstatic Neoplasms, Castration-ResistantRetrospective StudiesAdiponectinADIPOQ protein, humanBiomarkers, TumorLEP protein, humanLeptinProstate-Specific Antigenadipocytesadipokineadiponectinandrogen receptorbiochemical recurrencecastration-resistant prostate cancerleptinprostate cancer

Identifiers

PMID39201655
PMCPMC11354761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.